Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Welcomes Launch of Health Package Introducing EU Measures That Can... December 19, 2025 ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A... November 12, 2025 Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto August 20, 2020 Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 Load more HOT NEWS ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June 41-Year-Old Wrinkled Woman Who Ages 8 Times Faster Than Normal Is... Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... Holiday Coping and Enjoying
